• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Thatcher, Nick
    Wagstaff, John
    Mene, A R
    Smith, David B
    Orton, C
    Craig, P
    Affiliation
    CRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester M20 9BX, U.K.
    Issue Date
    1986-08
    
    Metadata
    Show full item record
    Abstract
    Seventy-nine patients with Stage III widely metastatic melanoma were prospectively randomised to a 'no treatment' control group who received on tumour progression DTIC (250 mg/m2 i.v. daily X 5) and Actinomycin D 1.5 mg/m2 on Day 1. A total of six courses at 3-week intervals was given. Chemotherapy was only given on progression of disease. The other group received initially Corynebacterium parvum (2 mg/m2) every 3 weeks for a maximum of eight courses and then the same chemotherapy on evidence of progressive disease. Minimum follow up time is 3 yr. The chemotherapy response rate (control 37%, C. parvum 24%) was not statistically different nor was the effect of chemotherapy on the site of individual metastases. Radiotherapy responses for irradiated soft tissue disease again were not significantly different, between the two patient groups. No significant differences in survival (control group median, 4 months, range 1-46; C. parvum median 3 months range 1-35) were observed and only one patient is alive at 35 months. The pattern of relapse was also similar in both groups. Reduction in haematological toxicity consequent on chemotherapy was not observed in the C. parvum-treated patients. No additional benefit was observed when C. parvum was followed by DTIC and Actinomycin D chemotherapy compared with the results from the chemotherapy given alone, although C. parvum on this schedule had minimal toxicity.
    Citation
    Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma. 1986, 22 (8):1009-14 Eur J Cancer Clin Oncol
    Journal
    European Journal of Cancer & Clinical Oncology
    URI
    http://hdl.handle.net/10541/108007
    DOI
    10.1016/0277-5379(86)90069-6
    PubMed ID
    3770045
    Type
    Article
    Language
    en
    ISSN
    0277-5379
    ae974a485f413a2113503eed53cd6c53
    10.1016/0277-5379(86)90069-6
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
    • Authors: Robidoux A, Gutterman JU, Bodey GP Sr, Hersh EM
    • Issue date: 1982 Jun 1
    • Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
    • Authors: Thatcher N, Mene A, Banerjee SS, Craig P, Gleave N, Orton C
    • Issue date: 1986 Feb
    • Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
    • Authors: Presant CA, Bartolucci AA, Smalley RV, Vogler WR
    • Issue date: 1979 Sep
    • Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
    • Authors: Balch CM, Murray D, Presant C, Bartolucci AA
    • Issue date: 1984 Apr
    • Dibromodulcitol (DBD), DTIC, and actinomycin-D in disseminated malignant melanoma. A phase I-II clinical trial.
    • Authors: Samson MK, Haas CD, Baker LH, Cummings G
    • Issue date: 1985 Apr
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.